The aims of the UCSF-GIVI CFAR are to support a multi-disciplinary environment that promotes basic, clinical, epidemiologic, behavioral, and translational research in the prevention, detection, and treatment of HIV infection and AIDS and to further the programs of NIH institutes by providing unique and effectively managed activities propelling HIV research. CFAR applies effective leadership, open communications, educational opportunities, sound resource management, and strategic planning to link CFAR members across sites and scientific disciplines. The Center's leadership is committed to proactive management, transparency and continued program monitoring, evaluation, and readjustment. CFAR maintains an effective partnership with the UCSF AIDS Research Institute and with the Center for AIDS Prevention Studies. To catalyze multidisciplinary research, the Center manages six scientific cores (Clinical and Population Sciences, Immunology, Virology, Specimen Banking, Pharmacology, and International). The Clinical and Population Sciences Core facilitates access to appropriate clinical cohorts. The International Core, focused on a growing portfolio in Uganda, will build in-country capacity and collaborate with the Fogarty International Center in training. Expansion to other African sites is expected. Core Directors are charged with member outreach and soliciting new investigators to take advantage of the cutting edge technologies and assays available within the cores. Success of the scientific cores is assessed by the quality of the multidisciplinary science they stimulate and by the publications and successful grants to which they contribute. The CFAR Administrative Core maintains an electronic network, including videoconferencing, to connect and inform all CFAR members, organizes scientific seminars and symposia, and implements financial systems to monitor and report all CFAR funds, ensuring maximum CFAR effectiveness. The Developmental Core funds pilot and basic science grants. It supports the next generation of HIV science through mentored pilot grants and an extremely successful and ambitious formal mentoring program. The success of the UCSF-GIVI CFAR is evident in the scientific accomplishments of its investigators, its ability to galvanize fundamentally new science through its focus on innovative multidisciplinary HIV research, and the significant institutional support it receives from UCSF, the San Francisco Veterans Affairs Medical Center and the J. David Gladstone Institutes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027763-19
Application #
7938742
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
1997-03-01
Project End
2012-08-31
Budget Start
2010-09-01
Budget End
2011-08-31
Support Year
19
Fiscal Year
2010
Total Cost
$3,401,797
Indirect Cost
Name
University of California San Francisco
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Haas, Andreas D; Zaniewski, Elizabeth; Anderegg, Nanina et al. (2018) Retention and mortality on antiretroviral therapy in sub-Saharan Africa: collaborative analyses of HIV treatment programmes. J Int AIDS Soc 21:
Dubé, Karine; Gianella, Sara; Concha-Garcia, Susan et al. (2018) Ethical considerations for HIV cure-related research at the end of life. BMC Med Ethics 19:83
Libby, Ashley Rg; Joy, David A; So, Po-Lin et al. (2018) Spatiotemporal mosaic self-patterning of pluripotent stem cells using CRISPR interference. Elife 7:
Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198
Jin, Harry; Ogunbajo, Adedotun; Mimiaga, Matthew J et al. (2018) Over the influence: The HIV care continuum among methamphetamine-using men who have sex with men. Drug Alcohol Depend 192:125-128
Manuzak, Jennifer A; Gott, Toni M; Kirkwood, Jay S et al. (2018) Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapy-Treated Human Immunodeficiency Virus-Infected Individuals. Clin Infect Dis 66:1872-1882
Shiboski, Caroline H; Baer, Alan N; Shiboski, Stephen C et al. (2018) Natural History and Predictors of Progression to Sjögren's Syndrome Among Participants of the Sjögren's International Collaborative Clinical Alliance Registry. Arthritis Care Res (Hoboken) 70:284-294
Hansen, Maike M K; Desai, Ravi V; Simpson, Michael L et al. (2018) Cytoplasmic Amplification of Transcriptional Noise Generates Substantial Cell-to-Cell Variability. Cell Syst 7:384-397.e6
Hogan, Louise E; Vasquez, Joshua; Hobbs, Kristen S et al. (2018) Increased HIV-1 transcriptional activity and infectious burden in peripheral blood and gut-associated CD4+ T cells expressing CD30. PLoS Pathog 14:e1006856
Sauceda, John A; Neilands, Torsten B; Johnson, Mallory O et al. (2018) An update on the Barriers to Adherence and a Definition of Self-Report Non-adherence Given Advancements in Antiretroviral Therapy (ART). AIDS Behav 22:939-947

Showing the most recent 10 out of 1541 publications